Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain.

Belletti D, Grabrucker AM, Pederzoli F, Menrath I, Vandelli MA, Tosi G, Duskey TJ, Forni F, Ruozi B.

Int J Pharm. 2018 May 30;543(1-2):300-310. doi: 10.1016/j.ijpharm.2018.03.061. Epub 2018 Mar 30.

PMID:
29608954
2.

Qualitative and semiquantitative analysis of the protein coronas associated to different functionalized nanoparticles.

Pederzoli F, Tosi G, Genovese F, Belletti D, Vandelli MA, Ballestrazzi A, Forni F, Ruozi B.

Nanomedicine (Lond). 2018 Feb;13(4):407-422. doi: 10.2217/nnm-2017-0250. Epub 2018 Jan 18.

PMID:
29345202
3.

Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer's disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery.

Vilella A, Belletti D, Sauer AK, Hagmeyer S, Sarowar T, Masoni M, Stasiak N, Mulvihill JJE, Ruozi B, Forni F, Vandelli MA, Tosi G, Zoli M, Grabrucker AM.

J Trace Elem Med Biol. 2018 Sep;49:210-221. doi: 10.1016/j.jtemb.2017.12.006. Epub 2017 Dec 27.

PMID:
29325805
4.

Development of a simple and sensitive liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) method for the determination of cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) and its metabolites in rat whole blood after oral administration of a single high dose of CBD.

Palazzoli F, Citti C, Licata M, Vilella A, Manca L, Zoli M, Vandelli MA, Forni F, Cannazza G.

J Pharm Biomed Anal. 2018 Feb 20;150:25-32. doi: 10.1016/j.jpba.2017.11.054. Epub 2017 Nov 28.

PMID:
29202305
5.

Analysis of cannabinoids in commercial hemp seed oil and decarboxylation kinetics studies of cannabidiolic acid (CBDA).

Citti C, Pacchetti B, Vandelli MA, Forni F, Cannazza G.

J Pharm Biomed Anal. 2018 Feb 5;149:532-540. doi: 10.1016/j.jpba.2017.11.044. Epub 2017 Nov 20.

PMID:
29182999
6.

Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders.

Duskey JT, Belletti D, Pederzoli F, Vandelli MA, Forni F, Ruozi B, Tosi G.

Int Rev Neurobiol. 2017;137:1-28. doi: 10.1016/bs.irn.2017.08.006. Epub 2017 Oct 16. Review.

PMID:
29132540
7.

Corrigendum to: EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION (International Journal of Pharmaceutics. 511 (1) (2016) 331-340).

Belletti D, Grabrucker AM, Pederzoli F, Menrath I, Cappello V, Vandelli MA, Forni F, Tosi G, Ruozi B.

Int J Pharm. 2017 Nov 25;533(1):321. doi: 10.1016/j.ijpharm.2017.10.019. No abstract available.

PMID:
29056147
8.

Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach.

Belletti D, Riva G, Luppi M, Tosi G, Forni F, Vandelli MA, Ruozi B, Pederzoli F.

Eur J Pharm Sci. 2017 Sep 30;107:230-239. doi: 10.1016/j.ejps.2017.07.020. Epub 2017 Jul 18.

PMID:
28728978
9.

Protein corona and nanoparticles: how can we investigate on?

Pederzoli F, Tosi G, Vandelli MA, Belletti D, Forni F, Ruozi B.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017 Nov;9(6). doi: 10.1002/wnan.1467. Epub 2017 Mar 15. Review.

PMID:
28296346
10.

Implementation of Portable Emissions Measurement Systems (PEMS) for the Real-driving Emissions (RDE) Regulation in Europe.

Giechaskiel B, Vlachos T, Riccobono F, Forni F, Colombo R, Montigny F, Le-Lijour P, Carriero M, Bonnel P, Weiss M.

J Vis Exp. 2016 Dec 4;(118). doi: 10.3791/54753.

11.

Apoferritin nanocage as streptomycin drug reservoir: Technological optimization of a new drug delivery system.

Ruozi B, Veratti P, Vandelli MA, Tombesi A, Tonelli M, Forni F, Pederzoli F, Belletti D, Tosi G.

Int J Pharm. 2017 Feb 25;518(1-2):281-288. doi: 10.1016/j.ijpharm.2016.12.038. Epub 2016 Dec 23.

PMID:
28017769
12.

Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin.

Belletti D, Pederzoli F, Forni F, Vandelli MA, Tosi G, Ruozi B.

Expert Opin Drug Deliv. 2017 Jul;14(7):825-840. doi: 10.1080/17425247.2017.1243528. Epub 2016 Oct 21. Review.

PMID:
27690258
13.

Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain.

Ruozi B, Belletti D, Pederzoli F, Forni F, Vandelli MA, Tosi G.

CNS Neurol Disord Drug Targets. 2016;15(9):1079-1091. Review.

PMID:
27633786
14.

EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION.

Belletti D, Grabrucker AM, Pederzoli F, Menrath I, Cappello V, Vandelli MA, Forni F, Tosi G, Ruozi B.

Int J Pharm. 2016 Sep 10;511(1):331-340. doi: 10.1016/j.ijpharm.2016.07.022. Epub 2016 Jul 12.

PMID:
27418565
15.

Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders.

Salvalaio M, Rigon L, Belletti D, D'Avanzo F, Pederzoli F, Ruozi B, Marin O, Vandelli MA, Forni F, Scarpa M, Tomanin R, Tosi G.

PLoS One. 2016 May 26;11(5):e0156452. doi: 10.1371/journal.pone.0156452. eCollection 2016.

16.

Nanoparticle transport across the blood brain barrier.

Grabrucker AM, Ruozi B, Belletti D, Pederzoli F, Forni F, Vandelli MA, Tosi G.

Tissue Barriers. 2016 Feb 25;4(1):e1153568. doi: 10.1080/21688370.2016.1153568. eCollection 2016 Jan-Mar. Review.

17.

PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity.

Belletti D, Tosi G, Forni F, Lagreca I, Barozzi P, Pederzoli F, Vandelli MA, Riva G, Luppi M, Ruozi B.

Eur J Pharm Biopharm. 2016 Feb;99:7-17. doi: 10.1016/j.ejpb.2015.11.007. Epub 2015 Nov 25.

PMID:
26625717
18.

Nanoimaging: photophysical and pharmaceutical characterization of poly-lactide-co-glycolide nanoparticles engineered with quantum dots.

Pederzoli F, Ruozi B, Pracucci E, Signore G, Zapparoli M, Forni F, Vandelli MA, Ratto G, Tosi G.

Nanotechnology. 2016 Jan 8;27(1):015704. doi: 10.1088/0957-4484/27/1/015704. Epub 2015 Nov 24.

PMID:
26597894
19.

Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice.

Valenza M, Chen JY, Di Paolo E, Ruozi B, Belletti D, Ferrari Bardile C, Leoni V, Caccia C, Brilli E, Di Donato S, Boido MM, Vercelli A, Vandelli MA, Forni F, Cepeda C, Levine MS, Tosi G, Cattaneo E.

EMBO Mol Med. 2015 Dec;7(12):1547-64. doi: 10.15252/emmm.201505413.

20.

Use of Polylactide-Co-Glycolide-Nanoparticles for Lysosomal Delivery of a Therapeutic Enzyme in Glycogenosis Type II Fibroblasts.

Tancini B, Tosi G, Bortot B, Dolcetta D, Magini A, De Martino E, Urbanelli L, Ruozi B, Forni F, Emiliani C, Vandelli MA, Severini GM.

J Nanosci Nanotechnol. 2015 Apr;15(4):2657-66.

PMID:
26353478
21.

Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): In Vivo Experiments.

Tosi G, Vilella A, Veratti P, Belletti D, Pederzoli F, Ruozi B, Vandelli MA, Zoli M, Forni F.

Mol Pharm. 2015 Oct 5;12(10):3672-84. doi: 10.1021/acs.molpharmaceut.5b00446. Epub 2015 Sep 1.

PMID:
26312414
22.

Application of Polymeric Nanoparticles for CNS Targeted Zinc Delivery In Vivo.

Chhabra R, Ruozi B, Vilella A, Belletti D, Mangus K, Pfaender S, Sarowar T, Boeckers TM, Zoli M, Forni F, Vandelli MA, Tosi G, Grabrucker AM.

CNS Neurol Disord Drug Targets. 2015;14(8):1041-53.

PMID:
26295815
23.

Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma.

Riva G, Lagreca I, Mattiolo A, Belletti D, Lignitto L, Barozzi P, Ruozi B, Vallerini D, Quadrelli C, Corradini G, Forghieri F, Marasca R, Narni F, Tosi G, Forni F, Vandelli MA, Amadori A, Chieco-Bianchi L, Potenza L, Calabrò ML, Luppi M.

Haematologica. 2015 Nov;100(11):e467-70. doi: 10.3324/haematol.2015.126854. Epub 2015 Jul 23. No abstract available.

24.

PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury.

Ruozi B, Belletti D, Sharma HS, Sharma A, Muresanu DF, Mössler H, Forni F, Vandelli MA, Tosi G.

Mol Neurobiol. 2015 Oct;52(2):899-912. doi: 10.1007/s12035-015-9235-x.

PMID:
26108180
25.

Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk.

De Luca G, Bosello SL, Berardi G, Rucco M, Canestrari G, Correra M, Mirone L, Forni F, Di Mario C, Danza FM, Pirronti T, Ferraccioli G.

Rheumatology (Oxford). 2015 Nov;54(11):1991-9. doi: 10.1093/rheumatology/kev204. Epub 2015 Jun 22.

PMID:
26106211
26.

Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles.

Vilella A, Ruozi B, Belletti D, Pederzoli F, Galliani M, Semeghini V, Forni F, Zoli M, Vandelli MA, Tosi G.

Pharmaceutics. 2015 Jun 19;7(2):74-89. doi: 10.3390/pharmaceutics7020074. Review.

27.

PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting.

Monsalve Y, Tosi G, Ruozi B, Belletti D, Vilella A, Zoli M, Vandelli MA, Forni F, López BL, Sierra L.

Nanomedicine (Lond). 2015;10(11):1735-50. doi: 10.2217/nnm.15.29.

PMID:
26080696
28.

Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma.

Belletti D, Tosi G, Riva G, Lagreca I, Galliania M, Luppi M, Vandelli MA, Forni F, Ruozi B.

Int J Pharm. 2015 Jul 25;490(1-2):85-93. doi: 10.1016/j.ijpharm.2015.05.029. Epub 2015 May 15.

PMID:
25987470
29.

Nanomedicine and neurodegenerative disorders: so close yet so far.

Tosi G, Vandelli MA, Forni F, Ruozi B.

Expert Opin Drug Deliv. 2015 Jul;12(7):1041-4. doi: 10.1517/17425247.2015.1041374. Epub 2015 Apr 26.

PMID:
25912814
30.

Functionalization of liposomes: microscopical methods for preformulative screening.

Belletti D, Vandelli MA, Tonelli M, Zapparoli M, Forni F, Tosi G, Ruozi B.

J Liposome Res. 2015;25(2):150-6. doi: 10.3109/08982104.2014.956221. Epub 2014 Sep 9.

PMID:
25203607
31.

Poly (D,L-lactide-co-glycolide) nanoparticles loaded with cerebrolysin display neuroprotective activity in a rat model of concussive head injury.

Ruozi B, Belletti D, Forni F, Sharma A, Muresanu D, Mössler H, Vandelli MA, Tosi G, Sharma HS.

CNS Neurol Disord Drug Targets. 2014;13(8):1475-82.

PMID:
25106629
32.

Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.

Guidi L, Marzo M, Andrisani G, Felice C, Pugliese D, Mocci G, Nardone O, De Vitis I, Papa A, Rapaccini G, Forni F, Armuzzi A.

Dig Liver Dis. 2014 Nov;46(11):974-9. doi: 10.1016/j.dld.2014.07.013. Epub 2014 Aug 2.

PMID:
25096964
33.

Nanotechnology and Alzheimer's disease: what has been done and what to do.

Ruozi B, Belletti D, Pederzoli F, Veratti P, Forni F, Vandelli MA, Tosi G.

Curr Med Chem. 2014;21(36):4169-85. Review.

PMID:
25039777
34.

Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release.

Chhabra R, Grabrucker AM, Veratti P, Belletti D, Boeckers TM, Vandelli MA, Forni F, Tosi G, Ruozi B.

Int J Pharm. 2014 Aug 25;471(1-2):349-57. doi: 10.1016/j.ijpharm.2014.05.054. Epub 2014 Jun 2.

PMID:
24882034
35.

Regression of endothelial dysfunction in patients with endometriosis after surgical treatment: a 2-year follow-up study.

Santoro L, D'Onofrio F, Campo S, Ferraro PM, Flex A, Angelini F, Forni F, Nicolardi E, Campo V, Mascilini F, Landolfi R, Tondi P, Santoliquido A.

Hum Reprod. 2014 Jun;29(6):1205-10. doi: 10.1093/humrep/deu074. Epub 2014 Apr 28.

PMID:
24777848
36.

Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport.

Tosi G, Vilella A, Chhabra R, Schmeisser MJ, Boeckers TM, Ruozi B, Vandelli MA, Forni F, Zoli M, Grabrucker AM.

J Control Release. 2014 Mar 10;177:96-107. doi: 10.1016/j.jconrel.2014.01.004. Epub 2014 Jan 11.

PMID:
24417968
37.

Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution.

Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, Boeckers TM, Forni F, Zoli M.

J Control Release. 2014 Jan 28;174:195-201. doi: 10.1016/j.jconrel.2013.11.023. Epub 2013 Dec 5.

PMID:
24316476
38.

Biodegradable device applied in flatfoot surgery: comparative studies between clinical and technological aspects of removed screws.

Ruozi B, Belletti D, Manfredini G, Tonelli M, Sena P, Vandelli MA, Forni F, Tosi G.

Mater Sci Eng C Mater Biol Appl. 2013 Apr 1;33(3):1773-82. doi: 10.1016/j.msec.2012.12.093. Epub 2013 Jan 8.

PMID:
23827635
39.

Nanoparticles engineered with rituximab and loaded with Nutlin-3 show promising therapeutic activity in B-leukemic xenografts.

Voltan R, Secchiero P, Ruozi B, Forni F, Agostinis C, Caruso L, Vandelli MA, Zauli G.

Clin Cancer Res. 2013 Jul 15;19(14):3871-80. doi: 10.1158/1078-0432.CCR-13-0015. Epub 2013 May 29.

40.

Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells.

Voltan R, Secchiero P, Ruozi B, Caruso L, Forni F, Palomba M, Zauli G, Vandelli MA.

Curr Med Chem. 2013;20(21):2712-22. Review.

PMID:
23627936
41.

Brain-targeted polymeric nanoparticles: in vivo evidence of different routes of administration in rodents.

Tosi G, Ruozi B, Belletti D, Vilella A, Zoli M, Vandelli MA, Forni F.

Nanomedicine (Lond). 2013 Sep;8(9):1373-83. doi: 10.2217/nnm.12.172. Epub 2013 Apr 8.

PMID:
23565661
42.

Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.

Tosi G, Bortot B, Ruozi B, Dolcetta D, Vandelli MA, Forni F, Severini GM.

Curr Med Chem. 2013;20(17):2212-25. Review.

PMID:
23458620
43.

Chemico-physical investigation of tenofovir loaded polymeric nanoparticles.

Belletti D, Tosi G, Forni F, Gamberini MC, Baraldi C, Vandelli MA, Ruozi B.

Int J Pharm. 2012 Oct 15;436(1-2):753-63. doi: 10.1016/j.ijpharm.2012.07.070. Epub 2012 Aug 4.

PMID:
22884838
44.

Platelet gel: applications in dental regenerative surgery.

Forni F, Marzagalli M, Tesei P, Grassi A.

Blood Transfus. 2013 Jan;11(1):102-7. doi: 10.2450/2012.0007-12. Epub 2012 Jul 4.

45.

Neurotrophic factors and neurodegenerative diseases: a delivery issue.

Ruozi B, Belletti D, Bondioli L, De Vita A, Forni F, Vandelli MA, Tosi G.

Int Rev Neurobiol. 2012;102:207-47. doi: 10.1016/B978-0-12-386986-9.00009-0. Review.

PMID:
22748832
46.

Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?

Tosi G, Badiali L, Ruozi B, Vergoni AV, Bondioli L, Ferrari A, Rivasi F, Forni F, Vandelli MA.

Nanomedicine (Lond). 2012 Mar;7(3):365-82. doi: 10.2217/nnm.11.98. Epub 2011 Sep 30.

PMID:
21957863
47.

The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum.

Bondioli L, Ludovisi A, Tosi G, Ruozi B, Forni F, Pozio E, Vandelli MA, Gómez-Morales MA.

Parasitology. 2011 Sep;138(11):1384-91. doi: 10.1017/S0031182011001119. Epub 2011 Aug 8.

PMID:
21819637
48.

Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.

Tosi G, Fano RA, Bondioli L, Badiali L, Benassi R, Rivasi F, Ruozi B, Forni F, Vandelli MA.

Nanomedicine (Lond). 2011 Apr;6(3):423-36. doi: 10.2217/nnm.11.11.

PMID:
21542682
49.

Novel polymeric/lipidic hybrid systems (PLHs) for effective Cidofovir delivery: preparation, characterization and comparative in vitro study with polymeric particles and liposomes.

Belletti D, Riva G, Tosi G, Forni F, Barozzi P, Luppi M, Vandelli MA, Ruozi B.

Int J Pharm. 2011 Jul 15;413(1-2):220-8. doi: 10.1016/j.ijpharm.2011.04.025. Epub 2011 Apr 21.

PMID:
21536117
50.

Sialic acid as a potential approach for the protection and targeting of nanocarriers.

Bondioli L, Ruozi B, Belletti D, Forni F, Vandelli MA, Tosi G.

Expert Opin Drug Deliv. 2011 Jul;8(7):921-37. doi: 10.1517/17425247.2011.577061. Epub 2011 Apr 22. Review.

PMID:
21510826

Supplemental Content

Support Center